Skip to content

FDA Clears Neurovalens’s Modius Sleep for Insomnia Treatment


Neurovalens successfully secured 510(k) clearance from the FDA on October 27, 2023 for its Modius Sleep device with relation to treatment of insomnia and/or anxiety.   The clearance was supported by data collected from a Phase III/pivotal clinical trial carried out in the UK and Ireland by Ulster University and in Hong Kong by PolyU University, Medical Device Network reports.  The 510(k) Premarket Notification also links to a clinical trial study titled Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control as a Means of Improving Glycemic Control in Adults with Type 2 Diabetes Mellitus which started on May 21, 2021 and continues to run.

The Belfast-headquartered global health company was founded by Dr. Jason McKeown in 2015.  Neurovalens’s Modius Sleep device is a wearable headset that delivers non-invasive electrical stimulation to the vestibular nerve of the wearer’s brain, eliminating the need for surgically implanted electrodes.  According to Neurovalens, users should wear the Modius Sleep device for 30 minutes per day prior to going to bed for the electrical pulse to influence the areas of the hypothalamus and brain stem that control circadian rhythm and sleep patterns.  Besides insomnia and anxiety, type 2 diabetes and obesity are also current targets of the Neurovalens technology.


, , , , , , , , ,

FDA Clears Neurovalens’s Modius Sleep for Insomnia Treatment Headshot

Mengmeng Du

Mengmeng Du is an associate in our Orange County office. Mengmeng helps clients with a variety of intellectual property matters with a focus on patent prosecution and litigation in the field of electrical and electronics engineering. Mengmeng received her J.D. degree from the University of Minnesota School of Law. While attending law school, she worked as an article editor of the Minnesota Journal of Law, Science, and Technology. Before attending law school, Mengmeng received her M.S. degree from Georgia Institute of Technology and worked as a special technologist at a patent law firm in Japan. Mengmeng worked as a summer associate with the firm in 2021 and joined the firm in 2022.

View all posts published by Mengmeng Du
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal